Search

… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen … on ARVOLearn , ARVO’s online learning platform. Details of ProQR’s presentation are as follows: Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal …

… ProQR annonce la publication dans Nature Medicine des données … CAMBRIDGE, Massachusetts, 18 déc. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société qui … commencer au cours du premier semestre 2019. À propos de ProQR ProQR Therapeutics s’efforce de changer les vies grâce …

… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated … of $6.50 per share. All of the shares were offered by ProQR. The closing included the full exercise of the …

… ProQR Announces Closing of Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … securities laws of any such state or jurisdiction.  About ProQR ProQR Therapeutics is dedicated to changing lives …

… ProQR Announces Clearance of IND Application to Start … affected by this devastating disease,“ said Noreen R. Henig, MD, Chief Medical Officer of ProQR. “Importantly, this trial is the first in ProQR’s …

… des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 Cet accès … à soutenir une évaluation et une approbation accélérées ProQR estime que l'Union européenne représentera un marché … et CAMBRIDGE, Mass., 29 juill. 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq : PRQR), une entreprise dédiée …

… ProQR to Present Top-Line Results from the Phase 1/2 Study of … Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … from the FDA as well as PRIME access by the EMA. About ProQR ProQR Therapeutics is dedicated to changing lives …